United States Patent 9,908,907 Scope, Claims, and Patent Landscape: Formula (VI) Compounds, HCl Salts, and Parenteral Compositions with Palonosetron
United States Patent 9,908,907 is claim-heavy on a narrow subset of formula (VI) structures, an HCl salt variant, and downstream parenteral composition claims that optionally add palonosetron. Based on the claim text provided, the effective scope is constrained by (i) fixed substituent defaults (R2, R5, R6 = hydrogen; m, p, s = zero) and (ii) only allowing R200 and R300 to vary between hydrogen and methyl. The combination claims tie directly to parenteral dosage forms and an added excipient system, then specifically recite palonosetron in dependent claims.
Given that no publication number, assignee, priority chain, specification-defined variables (formula (I) and (VI) structures), or prosecution history is provided here, a complete, defensible landscape for related continuations, family members, and Orange Book impacts cannot be produced from this input alone without risking inaccuracies.
What patents protect US 9,908,907’s formula (VI) compounds with R2/R5/R6 = hydrogen and m/p/s = zero?
Short answer: 9,908,907’s independent compound scope is limited to compounds defined by formula (VI) where R2, R5, R6 are hydrogen, m, p, s are zero, and R200 and R300 are each hydrogen or methyl. That makes the protected “chemical space” a small enumerated set (up to 4 stereochemically possible outcomes for those two variable positions, subject to the rest of formula (VI) being fixed by the specification).
How the claim constrains chemical scope
Claim 1 is an Markush-style claim with tight “lock-in” parameters:
- R2 = hydrogen
- R5 = hydrogen
- R6 = hydrogen
- m = 0
- p = 0
- s = 0
- R200 ∈ {hydrogen, methyl}
- R300 ∈ {hydrogen, methyl}
This means the only allowed variability is in the two specific positions R200 and R300. If the rest of formula (VI) is fixed (as the claim implies by not leaving other variables open), the compound set collapses from a broad scaffold to a narrow sub-series.
Enumerated sub-sets implied by R200 and R300
With two positions each choosing hydrogen or methyl:
- (R200 = H, R300 = H)
- (R200 = H, R300 = CH3)
- (R200 = CH3, R300 = H)
- (R200 = CH3, R300 = CH3)
If the scaffold includes stereocenters tied to those substituents, each could generate multiple stereoisomers. The claim as provided does not explicitly limit stereochemistry.
Salt form dependency and claim strategy
Claim 2 adds an HCl salt of the same constrained formula:
- “A chloride hydrochloride salt of a compound of formula (VI) …”
So the patent’s chemical coverage includes both the free base and at least one specific salt identity: the HCl (“chloride hydrochloride”) form.
What this implies for “design-around”
A competitor can potentially avoid Claim 1 while still using a close scaffold by:
- changing any of the locked variables (R2, R5, R6 away from hydrogen; m/p/s away from zero), or
- modifying positions that correspond to R200/R300 into substituents other than H or CH3, or
- using a different salt form instead of the specified HCl salt (though that risks other claims in the patent family not shown here).
Which US 9,908,907 claims cover HCl salts, and how narrow is that salt coverage?
Short answer: Claim 2 is the only salt claim you provided, and it is confined to the hydrochloride (“chloride hydrochloride”) salt of the formula (VI) compounds with the same locked substituents.
Claim 2 scope mechanics
Claim 2 is dependent or at least parallel to Claim 1, but it does not expand the chemical variability. It reuses the same constraints:
- R2 = H, R5 = H, R6 = H
- m = p = s = 0
- R200 and R300 ∈ {H, CH3}
Then it specifies the salt:
- “A chloride hydrochloride salt of a compound of formula (VI).”
This makes the salt aspect narrow and identifiable for litigation: the protected compound class exists only for the HCl salt of those constrained structures.
How do the composition claims in 9,908,907 broaden protection beyond single molecules?
Short answer: Claims 3 and 5 extend protection to parenteral compositions containing compounds of formula (I) (not formula (VI) as written in your claim text) or an HCl salt, plus liquid excipients. Dependent claims 4 and 6 add palonosetron.
Claim 3: parenteral composition with excipients
Claim 3 recites:
- “A parenteral pharmaceutical composition comprising a compound of formula (I): or a pharmaceutically acceptable salt thereof, and one or more liquid pharmaceutical excipients.”
Key scope elements:
- product type: parenteral
- active: compound of formula (I) (or salt)
- formulation: one or more liquid excipients
The claim is not limited by concentration, route (IV/IM/SC), pH, or specific excipient identity beyond “liquid excipients.”
Claim 4: adds palonosetron
Claim 4 recites:
- “The parenteral composition of claim 3, wherein the parenteral composition further comprises palonosetron, or a pharmaceutically acceptable salt thereof.”
This is a composition-of-interest hook with a specific co-ingredient. In practice, this becomes the main infringement risk lever for combination products if palonosetron is present as a co-formulated or co-delivered ingredient in the same parenteral regimen formulation.
Claim 5: HCl salt composition
Claim 5 repeats the composition structure but swaps the active form:
- “A parenteral pharmaceutical composition comprising a chloride hydrochloride salt of a compound of formula (I): and one or more liquid pharmaceutical excipients.”
So the salt-specific protection is carried into the parenteral formulation space.
Claim 6: HCl salt plus palonosetron
Claim 6 then further adds palonosetron:
- “The parenteral composition of claim 5 … further comprises palonosetron…”
Important scope observation: formula (I) vs formula (VI)
Your compound claims are framed around formula (VI), but the composition claims cite formula (I). Without the patent specification, it is not possible to confirm whether formula (VI) is a subset of formula (I), whether (VI) is the same scaffold expressed differently, or whether the claim numbering is transcribed from different claim sets.
For scope mapping, that distinction is critical because it determines whether a product that practices the composition claim must land on the exact locked variables of Claim 1/2 or instead on a broader set under formula (I).
What patent strength indicators exist based on claim structure alone?
Short answer: The claim set is structured for enforceability around a specific chemical subset and specific formulation combinations, with clear “must-have” elements for infringement. The tight Markush constraints reduce defensibility risk against prior art, but can reduce commercial coverage.
Strength factors in the provided claims
- Clear closed constraints in Claim 1/2: fixed hydrogen defaults and zero ring/chain parameters make the claim narrower. Narrow claims usually face fewer prior-art mapping issues, but fewer products fall inside scope.
- Salt identity is explicit in Claim 2: easier to assess infringement at the product specification level.
- Composition claims require parenteral format and liquid excipients: can be evaluated via product dossier and manufacturing/formulation documentation.
- Palonosetron co-ingredient is explicitly required in dependent claims: reduces ambiguity if the commercial product includes (or does not include) palonosetron in the same composition.
Weakness or limitation factors
- If formula (I) is broader than formula (VI): the composition claims may capture a larger set, but your input does not provide the linkage.
- If formula (I) is narrower than the clinical marketed compound: coverage may miss actual products unless they match the exact scaffold variables.
How does 9,908,907 affect generic or biosimilar entry risk?
Short answer: The patent as written (from your excerpts) is a chemical and formulation IP shield. It is not a biologics claim set. Generic risk depends on whether a generic would practice:
- the exact constrained formula (VI) compounds or HCl salt, and
- a parenteral liquid excipient product (and optionally) palonosetron in the same parenteral composition.
Generic scenario mapping
A generic of the same active could avoid infringement by:
- marketing a non-HCl salt if Claim 2/5/6 are central, or
- using a parenteral formulation that does not contain palonosetron in the same composition (relevant to Claims 4/6), or
- using a compound variant outside the Markush locked constraints (relevant to Claim 1/2).
Paragraph IV relevance
Paragraph IV challenges are driven by Orange Book listings and listed patents. Your input does not include the drug name, NDA/BLA number, or Orange Book patent associations. Without those, it is not possible to identify whether 9,908,907 is likely to be asserted in a Paragraph IV certification or whether it is even listed.
What does the inclusion of palonosetron imply for litigation and product design?
Short answer: Dependent Claims 4 and 6 create a specific co-formulation pathway: if the accused product includes palonosetron in the parenteral liquid composition, the infringement analysis will focus on presence/identity and the compound scaffold requirements under Claims 3/5.
Litigation anchor points
In practice, the factual disputes will be:
- whether the accused product is “parenteral” under the claim construction,
- whether “liquid pharmaceutical excipients” are present as required,
- whether palonosetron (or its salt) is included in the same composition, and
- whether the active ingredient matches the relevant formula (I) or formula (VI) constraints.
How many patents cover these palonosetron-containing parenteral compositions?
Short answer: From the information provided, only US 9,908,907 is identified. No additional family members, continuations, or continuations-in-part are provided, so a count of “how many patents” cannot be computed without importing external assumptions.
What is the likely expiration timing for 9,908,907 and what drives it?
Short answer: Expiration timing depends on the patent’s priority date, prosecution history (including potential PTA), and whether any patent term adjustment or extension applies. Your input does not include priority or expiration data, so a reliable exclusivity/expiration timeline cannot be stated.
Key limitations on drawing a full US landscape from only claim text
A complete US patent landscape typically requires:
- patent family members and related continuations,
- specification-defined formula details connecting (VI) and (I),
- assignee and inventor identities,
- cited prior art and prosecution outcomes,
- Orange Book linkage and FDA regulatory milestones for the corresponding NDA.
None of those are present in your input, and including them would require guesswork.
Key Takeaways
- Claim 1/2 scope is chemically narrow: R2/R5/R6 are hydrogen; m/p/s are zero; only R200 and R300 vary between hydrogen and methyl.
- HCl salt protection is explicit in Claim 2 and is carried into the parenteral salt formulation claims (Claim 5) and combination claims (Claim 6).
- Composition protection extends beyond the molecule to parenteral liquid excipient formulations (Claims 3 and 5).
- Palonosetron is a required co-ingredient in dependent claims (Claims 4 and 6), making palonosetron presence a direct infringement trigger for combination formulations.
- A defensible landscape requires more than claim text: family structure, assignee/publication data, and Orange Book/NDA linkage are not provided.
FAQs
-
Does US 9,908,907 cover parenteral formulations without palonosetron?
Yes for Claims 3 and 5 as provided, since palonosetron is only required in Claims 4 and 6.
-
Can a product avoid infringement by switching from HCl to another salt?
Potentially for the salt-specific claims (Claim 2, Claim 5, Claim 6), since those require “chloride hydrochloride.”
-
If a competitor uses the same scaffold but changes R200 or R300 beyond H or methyl, is it outside Claim 1?
Yes, based on Claim 1’s explicit limitation of R200 and R300 to hydrogen or methyl.
-
Do the composition claims depend on the same substituent constraints as Claim 1/2?
They reference a different formula label (formula (I) vs formula (VI) in your excerpt), so the linkage cannot be asserted from your text alone.
-
Is this a biologics-style (biosimilar) patent risk profile?
No. The claims provided are for parenteral pharmaceutical compositions and specific chemical structures, not biologic modalities.
References (APA)
- US Patent 9,908,907, claim text as provided by the user.
